Pharming Group (OTCMKTS:PHGUF) Releases Quarterly Earnings Results

Key Points

• Pharming Group reported quarterly EPS of ($0.01), while revenue came in at $72.45 million, below analyst expectations of $92.06 million.
• The biotechnology company posted a return on equity of 4.68% and a net margin of 3.30%, indicating modest profitability despite the earnings miss.
• Shares of Pharming Group were flat at $1.25 after the report, with the stock trading near the lower end of its 52-week range of $0.96 to $2.17.

Pharming Group (OTCMKTS:PHGUF - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports. Pharming Group had a return on equity of 4.68% and a net margin of 3.30%.The firm had revenue of $72.45 million for the quarter, compared to analyst estimates of $92.06 million.

Pharming Group Stock Performance

Shares of Pharming Group stock remained flat at $1.25 during mid-day trading on Friday. 5,071 shares of the company's stock traded hands, compared to its average volume of 390. Pharming Group has a one year low of $0.96 and a one year high of $2.17. The company has a market cap of $836.96 million, a PE ratio of 62.39 and a beta of 0.55. The stock has a fifty day moving average of $1.60 and a 200-day moving average of $1.65. The company has a quick ratio of 2.03, a current ratio of 2.59 and a debt-to-equity ratio of 0.39.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.